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Abstract
The purpose of this document,a result of the harmonisation and revision of Guidelines published separately by the SIMFER, 
SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and vari-
ous grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, 
prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of 
the Italian Scientific Associations involved in the project (SIE, SIGG, SIMFER, SIMG, SIMI, SIOMMMS, SIR, and SIOT).
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Definition
Osteoporosis is a systemic skeletal disease characterized by 
a reduction in bone mass and qualitative skeletal changes 
(macro- and microarchitecture, material properties, geom-
etry, and micro-damage) that cause an increase in bone fra-
gility and higher fracture risk. There are two forms of the 
disease: (a) primary osteoporosis, which includes juvenile, 
postmenopausal, and male and senile osteoporosis; and (b) 
secondary osteoporosis, which is caused by a large number 
of diseases and medications.
Fragility fractures may occur in almost all skeletal seg-
ments, but the preferential locations are the vertebral col-
umn, the proximal ends of the femur and humerus, and the 
distal end of the radius (Colles fracture). Trauma due to a 
fall is by far the most frequent cause of fractures affecting 
long bones (femur, humerus, and radius), while it is more 
difficult to determine the cause and the exact time of fragility 
fractures of the vertebral body, which often go undiagnosed.
During patient evaluation, there are some clinical history 
details that can suggest a vertebral fracture: recent trauma, 
prolonged use of corticosteroids, age, structural spinal 
deformity, loss of height > 6 cm, and a distance between 
the last rib and the iliac crest < 2 fingers. It is, therefore, 
advisable to carefully evaluate the presence of dorso-lumbar 
pain, progressive loss of height, or dorsal kyphosis, which 
may result in alterations of the respiratory or gastrointestinal 
functions.
Primary osteoporosis
(a) Juvenile osteoporosis
The expression juvenile osteoporosis is commonly used 
to indicate a form of osteoporosis found in childhood and 
adolescence: this disease is mostly due to genetic mutations 
that can lead to quantitative or qualitative alterations in the 
connective tissue component of bone (as in osteogenesis 
imperfecta, which is also characterized by extra-skeletal 
alterations), or to an altered osteoblastic activity with the 
particular involvement of the trabecular bone (as in the auto-
somal dominant form caused by inappropriate activation of 
the Wnt-β catenin signal). It can also be secondary to leu-
kaemia, prolonged immobilisation, or chronic inflammatory 
diseases; or it can be due to the chronic administration of 
drugs such as anti-epileptics and glucocorticoids. When it 
is not possible to identify possible causes of bone loss and 
fragility fractures, this condition is referred to as juvenile 
idiopathic osteoporosis.
In accordance with the Pediatric Official Positions of the 
International Society for Clinical Densitometry (ISCD), the 
diagnosis of osteoporosis in childhood is made on the basis 
of a history of one or more vertebral fragility fractures, or of 
a history of at least two fractures of the long bones before the 
age of 10, or of three or more long bone fractures before the 
age of 19 in the absence of local pathologies, high-energy 
trauma, and bone mineral density (BMD) Z-score ≤ 2.0 
standard deviation (SD) at the lumbar spine or total body 
less head (TBLH) scans.
(b) Postmenopausal osteoporosis
Postmenopausal osteoporosis is the most frequent pri-
mary form of the pathology, and is due to oestrogen defi-
ciency associated with menopause, which provokes an 
acceleration of bone loss due to age. It is characterized by 
rapid loss of trabecular bone mass with perforation of the 
trabecular bone, while cortical bone is partially spared. This 
loss is responsible for fragility fractures due to load bear-
ing, especially by the vertebrae and the distal radius. It is 
also generally characterized by a high bone turnover rate, 
with bone marrow expansion, and a prevalence of increased 
endosteal resorption, and also by inhibition of periosteal 
bone formation. BMD as determined by dual-X-ray absorp-
tiometry (DXA) is unanimously considered to be the most 
important predictor of osteoporotic fractures, and is indi-
cated, according to Italian Ministerial Decree regulating 
Essential Assistance Levels (EAL), in women of any age, 
in the presence of a major risk factor (for example, previ-
ous fragility fracture caused by minimal trauma, maternal 
family history of osteoporotic fracture at less than 75 years 
of age, menopause before 45 years of age, body mass index 
(BMI) < 19 kg/m2, and prolonged glucocorticoid therapy) 
and, for postmenopausal women only, the presence of at 
least three or more of the following minor risk factors:
1. Age greater than 65 years
2. Family history of severe osteoporosis
3. Premenopausal amenorrhoea for a period greater than 
6 months
4. Inadequate calcium intake (< 1200 mg/day)
5. Smoking > 20 cigarettes/day
6. Alcoholism (> 60 g/day)
(c) Male osteoporosis.
Osteoporosis is a major public health problem for men, 
as well; in fact, more than 20% of all hip fractures occur in 
males, and the incidence of vertebral fractures is about half 
that reported in women. Male osteoporosis is frequently sec-
ondary (about two-thirds of cases in males versus one-third 
in females), so it is always advisable to exclude other patho-
logical conditions associated with osteoporosis (Table 1). 
Moreover, in men, the BMD DXA technique is the method 
of choice to determine fracture risk, and it is indicated, 
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according to EAL, at any age, if there is a major risk factor 
(for example, fragility fracture, prolonged steroid therapy) 
or in the presence of three or more of the following minor 
risk factors for men over the age of 60 years:
1. Family history of severe osteoporosis
2. Underweight (BMI < 19 kg/m2)
3. Inadequate calcium intake (< 1200 mg/day)
4. Smoking > 20 cigarettes/day
5. Alcoholism (> 60 g/day).
Although densitometric criteria for the diagnosis of oste-
oporosis in males are not based on levels of evidence similar 
to those for females, currently, the accepted diagnostic den-
sitometric cutoff for the definition of male osteoporosis is a 
T-score < − 2.5 SD compared to young adult male subjects 
[1–4].
Secondary osteoporosis
Primary osteoporosis should always be distinguished from 
forms of secondary osteoporosis (Table 1).
Due to special diagnostic and therapeutic implications 
closely related to secondary osteoporosis management, we 
will provide herein indications for some of the most typical 
or frequent forms of this condition.
(a) Glucocorticoid-induced osteoporosis Chronic exposure 
to glucocorticoids, both due to increased endogenous 
synthesis (Cushing’s syndrome), and to exogenous 
intake (treatment of inflammatory or autoimmune 
diseases), is an important cause of osteoporosis and 
fractures. Glucocorticoids, in fact, stimulate resorp-
tion and, above all, reduce bone formation by inhib-
iting osteoblast proliferation and differentiation, and 
promoting osteoblast and osteocyte apoptosis. The loss 
of bone mass caused by glucocorticoids begins early, 
and is more pronounced during the first 6–12 months, 
especially at the level of the trabecular bone (vertebral 
fractures, in particular, may occur early after the begin-
ning of steroid therapy). Fragility fractures occur in 
between 30 and 50% of patients within the first 5 years 
of chronic glucocorticoid therapy, and their probability 
is further increased if other risk factors are present, 
such as old age, previous fractures and, in women, 
menopause. The incidence of fractures is related to the 
dose and duration of glucocorticoid therapy, and is also 
influenced by the underlying disease for which it was 
prescribed (e.g., rheumatoid arthritis and inflammatory 
bowel disease). Although lower doses are less harm-
ful than higher ones, a threshold below which no bone 
damage occurs is controversial. The negative impact on 
bone health exerted by glucocorticoids administered by 
inhalation is still a very controversial topic: undoubt-
edly, their use is much less harmful to bone, in contrast 
to systemic administration, although doses > 800 mcg/
day of budesonide (or equivalent), especially if pro-
longed, may be associated with accelerated loss of bone 
mass and increased risk of fractures. In glucocorticoid-
induced osteoporosis, the risk of fractures is much 
higher than could be expected based on the patient’s 
densitometric values, and decreases rapidly after dis-
continuation of treatment.
(b) Organ transplant osteoporosis The estimated preva-
lence of fragility fractures is approximately 10–15% 
in patients waiting for solid organ transplants (kidney, 
heart, liver, and lung), due to the negative effects of the 
underlying condition on bone tissue. After transplant, 
the percentage of patients with osteoporosis increases 
dramatically. Bone loss is greatest in the first year after 
surgery, but can also persist, albeit at a slower pace, 
Table 1  Causes of secondary osteoporosis
Endocrine or metabolic conditions Rheumatic conditions
 Hyperparathyroidism  Rheumatoid arthritis
 Hypogonadism  LES
 Thyrotoxicosis  Ankylosing spondylitis
 Hyperadrenocorticism  Psoriatic arthritis
 Diabetes mellitus  Scleroderma
 Hyperprolactinaemia Renal conditions
 GH deficit  Chronic renal failure
 Acromegaly  Idiopathic hypercalciuria
Blood conditions  Renal tubular acidosis
 Leukaemia Other conditions
 Multiple myeloma  Anorexia nervosa
 Systemic mastocytosis  Cystic fibrosis
 Thalassemia  COPD
Gastrointestinal conditions  Parkinson’s disease
 Celiac disease  Multiple sclerosis
 Gastrectomy and gastric bypass Drug-induced
 Intestinal malabsorption  Glucocorticoids
 Inflammatory bowel disease  l-Thyroxin suppressive 
therapy
 Chronic liver disease  Heparin and oral
 Primary biliary cirrhosis  Anticoagulants (AVK)
Genetic conditions  Anticonvulsants
 Osteogenesis imperfecta  Aromatase inhibitors
 Ehler–Danlos syndrome  Anti-androgens
 Gaucher’s disease  GnRH antagonists
 Glycogen storage disease  Immunosuppressives
 Hypophosphatemia  Anti-retrovirals
 Hemochromatosis  Thiazolidinediones
 Homocystinuria  Proton pump inhibitors
 Cystic fibrosis  Selective serotonin
 Marfan syndrome  Re-uptake inhibitors (SSRI)
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during subsequent periods. During the first 3 years after 
a transplant, the percentage of vertebral fractures due 
to bone fragility reaches a peak, and affects approxi-
mately 30–40% of patients. The main fracture-inducing 
factor is the immunosuppressive therapy, in particular, 
the use of cortisone, which is initially administered at 
very high doses, and, in the majority of patients, for an 
indefinite period; other relevant risk factors common 
to all types of transplants (at least in the long term) 
are greater age and female gender. Even the intrinsic 
factors relating to organ disease can be involved in the 
development of bone fragility: the most representative 
example of this specific form of osteoporosis is persis-
tent, very long-term severe forms of secondary hyper-
parathyroidism, which can affect up to 50% of patients 
after a kidney transplant, even when the transplant is 
functional.
(c) Drug osteoporosis Many types of drugs are associated 
with osteoporosis and fragility fractures. Many of these 
associations are derived from data obtained from epi-
demiological and retrospective studies, and in many 
cases, the incidence level is quite low. In addition to 
steroid therapy, it is now well known that aromatase 
inhibitors and GnRH are associated with increased risk 
of fragility fractures. A significantly increased risk of 
vertebral fractures and hip fractures has been associ-
ated with the use of proton pump inhibitors (PPI), espe-
cially if used for more than 12 months. In the case of 
serotonin re-uptake inhibitors (SSRIs), association with 
hip fracture appears within the first year of use of this 
drug in both genders, especially in those patients over-
70. A retrospective study demonstrates that in patients 
adhering to alendronate treatment, the combination 
with SSRIs is accompanied by a higher risk of major 
osteoporotic fractures.
  Levothyroxine (when administered in suppressive 
doses) is associated with an increased risk of fracture. 
The use of pioglitazone and rosiglitazone is strongly 
associated with a significant increased (three to four-
fold) risk of fracture of the hip and humerus in post-
menopausal women. There is extensive literature about 
the association between the use of some first-generation 
anticonvulsants (carbamazepine, phenobarbital, and 
phenytoin) in epileptic patients, especially if used in 
polytherapy, and low bone mass, while the risk of hip 
fracture increases from 2 to 6 times. Long-term use 
of unfractionated heparin leads to an increased risk of 
fracture (+ 2.5 to 5%), while there are no data about 
low-molecular-weight heparin use. On the other hand, 
the risk of fractures due to warfarin is controversial 
[5–10].
Epidemiological remarks
The epidemiological impact of osteoporosis is impressive. 
In Italy, about 3.5 million women and 1 million men suffer 
from osteoporosis, and, over the next 25 years, the percent-
age of the over-65 population will increase by 25%, so a 
proportional increase of this condition is to be expected. In 
the over-50 population, the number of hip fractures exceeds 
90,000, and in 2010, more than 70,000 vertebral fractures 
were reported by emergency services, but considering that 
many of these fractures go undiagnosed, it is believed that 
the actual figure is at least ten times greater.
It should be remembered that osteoporotic fractures of the 
hip and spine increase the relative risk of mortality. For hip 
fractures, it is about 5–8 times greater in the first 3 months 
after the event, decreasing over the following 2 years, but 
remains high at the 10-year follow-up; in absolute terms 
the incidence is up to 9% at 1 month after the event, and 
36% at 1 year, substantially comparable to stroke and breast 
cancer and four times greater than for endometrial carci-
noma. Moreover, 50% of women with hip fracture suffer 
from a substantial reduction in their level of self-sufficiency 
which, in approximately 20% of cases, involves long-term 
institutionalisation.
Colles’ fracture is also an early and sensitive marker of 
skeletal fragility, predisposing the patient to additional frac-
tures, in particular of the hip.
The economic implications of such a widespread disease 
are naturally very important: it is estimated that, in Italy, the 
cost of treatment of osteoporotic fractures is greater than 
7 billion Euros per year, of which “only” 360,000 are for 
secondary drug prevention. Proximal femur fractures, in 
particular, contribute to 60% of total costs, vertebral frac-
tures for 4%, wrist for 1%, while the remaining 35% is by 
other fractures. To this, of course, must be added the cost of 
pharmacological therapies and social spending (work days 
lost, disability, etc.).
Fragility fractures cause complex disability, significant 
morbidity, reduction in quality of life, and functional limita-
tions. A patient with osteoporosis requires comprehensive 
care, multi- and interdisciplinary intervention, and an indi-
vidual rehabilitation plan consisting of programmes ori-
ented towards specific areas of intervention. Based on the 
International Classification of Functioning, Disability and 
Health (ICF), the typical spectrum of functional problems 
experienced by subjects with osteoporosis (osteo-metabolic 
balance, motor function, posture, balance, coordination, 
mobility, gait, and quality of life) have been defined. The 
most relevant ICF categories for osteoporotic patients have 
recently been defined and implemented in a specific “ICF 
Core Set for Osteoporosis” [11–15].
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Risk factors
Fracture pathogenesis must take into account the many fac-
tors that influence both bone strength as well as frequency 
and type of trauma. Risk of osteoporotic fracture is deter-
mined by a combination of factors that act mainly through 
a reduction of BMD, factors that are partially or totally 
independent of BMD (bone tissue characteristics) and extra-
osseous factors that cannot be evaluated by means of BMD. 
The distinction is obviously not inflexible, and several risk 
factors act simultaneously through multiple mechanisms. In 
patients with multiple risk factors, fracture risk is higher than 
in patients with a single risk factor, including an isolated 
reduction in BMD. As a result, the determination of BMD 
can adequately diagnose osteoporosis (diagnostic threshold), 
while the identification of high fracture risk patients needing 
specific drug treatment (therapeutic threshold) requires an 
evaluation of combined BMD and independent risk factors.
(a) Age The incidence of osteoporotic fractures increases 
exponentially with age. The risk of fracture associated 
with advancing age is only partially due to BMD reduc-
tion, and depends largely on other factors, such as qual-
itative alterations in bone structure, increase in the fre-
quency of falls, and slowdown of protective responses. 
Thus, for a given BMD, fracture risk is higher in older 
people than in younger people.
(b) Family history of fragility fractures A family history of 
fractures, especially of the femur, influences fracture 
risk independently of BMD, and is the most valuable 
prognostic indicator.
(c) Previous fractures In both genders, the previous fra-
gility fractures are an important risk factor for subse-
quent fractures, irrespective of BMD. All previous non-
traumatic fractures increase the risk of new fractures, 
although, to varying degrees, also depending on their 
location and number. Special prognostic relevance is 
given to vertebral (including morphometric fractures), 
wrist, femur, and humerus fractures. Subjects with 
three or more vertebral fractures, risk new fractures 
almost ten times more than those who do not experi-
ence similar previous events, and 2–3 times more than 
those who have only one fracture. As regards mild ver-
tebral fractures, these represent a risk factor for more 
vertebral fractures, while their negative prognostic sig-
nificance regarding non-vertebral fractures is uncertain.
(d) BMD BMD reduction is a significant risk factor for 
fractures: this depends on peak bone mass attained at 
the height of bone development, and bone loss related 
to menopause and ageing, and is influenced by genetic 
and nutritional factors, lifestyle, behaviour, various dis-
eases, and drug treatment.
  Numerous prospective epidemiological studies car-
ried out mostly by measuring BMD using the DXA 
technique at axial locations (femoral neck, total hip, 
and lumbar spine) have ascertained that any reduction 
in BMD SD increases the risk of fracture 1.5–3 times.
(e) Smoking Smoking (cigarettes in particular) is an inde-
pendent risk factor for vertebral and appendicular frac-
tures.
(f) Immobility Is considered a moderate risk factor.
(g) Comorbidities Many pathological conditions are asso-
ciated with increased rates of fracture risk. In many of 
these conditions, it is believed that the risk is medi-
ated by BMD reduction. However, comorbidities 
often involve different mechanisms, including chronic 
inflammation, altered bone quality, impairment of 
general health conditions, specific complications, 
decreased mobility, decreased muscle mass and mus-
cle function (sarcopenia), increased risk of falling, and 
vitamin D deficiency, which is very frequent in Italy, 
especially in the elderly population. The diseases most 
frequently associated with an increased risk of fracture 
are: rheumatoid arthritis, inflammatory bowel diseases, 
untreated hypogonadism (GH deficiency, oophorec-
tomy or bilateral orchiectomy, androgen deprivation 
in men with prostate cancer, chemotherapy, or adju-
vant hormonal therapy in women with breast cancer), 
organ transplants, COPD, diabetes mellitus types 1 and 
2, disabling motor diseases, and prolonged immobility 
(Parkinson’s disease, stroke, muscular dystrophy, and 
spinal cord injury).
(h) Risk factors for falls These are of fundamental impor-
tance, especially in older individuals. The most impor-
tant of these are deafness, visual disorders, neuro-
muscular disorders, Parkinson’s disease, dementia, 
malnutrition, alcoholism, and vitamin D deficiency. 
Environmental factors capable of promoting falls such 
as physical barriers, carpets, slippery floors, poor light-
ing environments, etc. must also be corrected.
Overall assessment of fracture risk
Using specific algorithms, it is possible to perform an inte-
grated assessment of BMD including the most important 
risk factors, partially or wholly independent of BMD, so 
as to arrive at a more accurate estimate of middling-term 
(5–10 years) risk of fragility fractures, and, therefore, iden-
tification of subjects in whom drug treatment is the most 
appropriate therapeutic solution.
The definition of clinical risk factors independent of 
BMD included in these algorithms has been considered in 
a series of studies and meta-analyses that have identified 
their importance, and also their ease of identification and 
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quantification. The greater importance of some BMD inde-
pendent clinical risk factors (diabetes mellitus, androgen 
deprivation therapy, and use of aromatase inhibitors) has 
also resulted, in the long run, in their being significantly 
more considered when establishing criteria for the reim-
bursement of drug costs in cases of osteoporosis in Italy 
(Note 79, AIFA). Currently, to evaluate multiple risk-factor 
combinations, it is possible to use mathematical algorithms 
that quantify risk in terms of “10-year fracture risk.” One 
of the algorithms most commonly used today is  FRAX® 
(http://www.shef.ac.uk/FRAX/), which, however, has inher-
ent limitations, due mainly to the use of dichotomous vari-
ables only. In Italy, to improve the accuracy of  FRAX®, it 
was converted into a version known as “Derived Fracture 
Risk Assessment” or DeFRA (http://defra -osteo poros i.it). 
It only provides an estimate of risk similar to  FRAX® on 
the basis of continuous variables (age, BMI, BMD), but is 
more accurate as it evaluates other clinical risk factors in 
a more detailed (e.g., the location and number of previous 
fractures) and complete manner (e.g., other osteoporosis-
inducing drugs, other comorbidities, not only femoral but 
spine BMD too). The data contained in Health Search, a gen-
eral medicine database, containing data for about 1 million 
patients aged between 50 and 85, have permitted us to verify 
that the incidence for a 5-year period (per 1000 people/year) 
of osteoporotic fractures is 11.56 (95% CI 11.33–11.77) in 
females, and 4.91 (95% CI 4.75–5.07) in males. Predictive 
factors for fragility fractures prove to be in line with those 
provided by the  FRAX® algorithm, leading to the develop-
ment of a present-day score system called FraHS, available 
to general practitioners, and, therefore, of immediate use in 
favour of the entire population [1, 16–23].
Diagnosis
Diagnosis of osteoporosis and assessments of fragility frac-
ture risks are based on case history, physical examination, 
laboratory, and diagnostic tests.
Case histories require the collection of information 
related to patients’ medical histories, lifestyle, and appro-
priate assessment of risk factors. Of particular importance 
is the history of previous fragility fractures and family his-
tory of fractures. It is common knowledge that a history of 
femur fractures in parents significantly increases the risk 
of hip fractures, and, to a lesser extent, of all osteoporotic 
fractures, in their offspring. Finally, the presence of comor-
bidities should be carefully investigated, any medication that 
may interfere with bone metabolism and, in women, their 
gynaecological history, and the age of the onset of meno-
pause are also significant.
A physical examination should evaluate the patient’s 
posture, especially if there is an increase in kyphosis or a 
decrease in height that may indicate the presence of one or 
more vertebral deformities.
Diagnostic imaging
Diagnostic imaging of osteoporosis and fragility fractures 
includes evaluation of BMD using DXA, quantitative com-
puterized tomography (QCT) or ultrasound (QUS) studies, 
and conventional radiology to diagnose spinal fractures.
(a) Computerized X-ray bone densitometry
X-ray densitometry (DXA) makes it possible to measure 
bone mass and bone mineral density (BMD) in g/cm2 of 
projected bone area accurately and precisely.
According to the WHO, densitometric diagnosis of osteo-
porosis is based on technical DXA evaluation of mineral 
density, to be compared to the average of healthy adults of 
the same gender (peak bone mass). The unit of measure-
ment is represented by SD from the mean bone mass peak 
(T-score). BMD can also be expressed by means of com-
parison to average values for subjects of the same age and 
gender (Z-score). It has been observed that risk of fracture 
begins to increase exponentially with densitometric T-score 
values of < − 2.5 SD that, according to the WHO, represent 
the threshold level by which to diagnose the presence of 
osteoporosis. Bone densitometry represents, therefore, a 
diagnostic test for osteoporosis and risk of fracture, just as 
blood pressure measurement is used to diagnose hyperten-
sion and, therefore, the risk of having a stroke. According 
to the WHO, when interpreting the results of BMD, the fol-
lowing definitions should be used:
1. Normal BMD is defined by a T-score between 2.5 and 
− 1.0 (therefore, patient BMD lies at between 2.5 SD 
above the mean and 1 SD below the mean for a healthy 
young adult of the same sex).
2. Osteopaenia (low BMD) is defined by a T-score of 
between − 1.0 and − 2.5 SD.
3. Osteoporosis is defined by a T-score equal to or less than 
− 2.5 SD.
4. Severe (or established) osteoporosis is defined by a 
T-score below − 2.5 SD and by the simultaneous pres-
ence of one or more fragility fractures.
A densitometric assay is considered the best predictor of 
osteoporotic fracture risks, although it should be noted that 
diagnosis of osteoporosis could not be established on the 
basis of densitometry alone, but always require adequate 
clinical evaluation.
The T-score diagnostic threshold, moreover, does not 
coincide with the therapeutic threshold, since other factors, 
skeletal and extra-skeletal alike, influence both the risk of 
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fracture for individual subjects, and the decision whether or 
not to undertake pharmacological treatment.
Since most clinically relevant osteoporotic fractures occur 
at vertebral and femoral level, the most frequently measured 
sites are the lumbar spine and proximal femur. Densitometric 
examinations can be carried out at the level of the lumbar 
spine (L1–L4), of the total hip and the femoral neck alone. 
The lowest T-score value for these three sites is considered 
the densitometry result.
The accuracy of densitometric results may be reduced 
by the possible presence of interfering factors that need to 
be taken into due consideration by those who refer to or 
perform this measurement. For example, a fractured ver-
tebra or one with postarthritic focal accumulation must be 
excluded from the densitometric analysis, and at least two 
adjacent lumbar vertebrae evaluated. For this reason, lumbar 
densitometry is often inaccurate after the age of 65 due to 
interference of osteoarthritis signs, extra-skeletal calcifica-
tions, or vertebral fractures; therefore, after this age, it is 
preferable to assess femoral densitometry.
Peripheral measurements of the forearm are reserved for 
special circumstances and in particular for patients in whom 
lumbar or femoral evaluation is not possible, or not accu-
rate, or if they are severely obese, or suffer from primary 
hyperparathyroidism.
Recently, DXA software has been developed, which, in 
addition to densitometry, makes it possible to evaluate a 
number of geometric parameters related to bone strength, 
such as HSA (hip structural analysis) and TBS (trabecular 
bone score). HSA evaluates strength indices and geomet-
ric parameters of the proximal femur. Of these, the most 
significant are cross-sectional area, cross-sectional moment 
of inertia, section modulus, and buckling ratio. TBS is a 
software that processes degrees of inhomogeneity in spinal 
densitometry scans, while providing indirect information 
on trabecular microarchitecture. Hitherto published studies 
show that TBS improves, compared to BMD measurement 
alone, the ability to predict fracture risks. It seems to play 
a particularly significant role in the classification of those 
at risk for fragility fracture with BMD values within the 
normal or osteopaenia range. This application is approved 
by the FDA, but its usefulness in clinical practice has not 
been clearly defined.
The Italian Ministerial Decree regulating Essential Assis-
tance Levels (EAL) considers risk factors, in the presence 
of which densitometric investigation is indicated [3, 24–27].
(b) Bone ultrasound
Ultrasound studies (Quantitative US, QUS) provide two 
parameters (speed and attenuation) that are indirect indi-
ces of bone mass and structural integrity, and are meas-
ured mainly at two sites, the phalanges of the hand and the 
calcaneus. It has been demonstrated that ultrasound param-
eters used to predict the risk of osteoporotic fractures (ver-
tebral and femoral) are not inferior to lumbar or femoral 
DXA, both in postmenopausal women and in men. This 
technique does not represent a direct measurement of bone 
density, and therefore, discordant results between QUS and 
DXA do not necessarily indicate an error, but, rather, that the 
QUS parameters are independent predictors of fracture risk 
influenced by other characteristics of bone tissue. Moreo-
ver, for this reason, QUS cannot be used for the diagnosis 
of osteoporosis according to WHO criteria (T-score < − 2.5 
SD). An important limitation of QUS is represented by the 
heterogeneity of the devices that provide values not always 
related to each other; however, it can be useful when it is 
not possible to perform a lumbar or femoral DXA, and may 
be recommended for epidemiological investigations and the 
first-level screening, considering its relatively low costs, 
easy portability, and the absence of radiation. In general, 
a reduced ultrasound value, in the presence of other clini-
cal fracture risk factors, can justify therapeutic intervention, 
while a high ultrasound value, in the absence of risk factors, 
indicates unlikely probability of osteoporotic fractures, and, 
therefore, the inutility of further investigation.
(c) Conventional radiology
Traditional radiology This makes it possible to diagnose 
osteoporosis fractures in the most commonly involved sites 
(spine, ribs, pelvis, proximal femur, proximal humerus, dis-
tal radius, and calcaneus). In particular, radiological studies 
and semi-quantitative or quantitative vertebral morphometry 
allow the identification and correct classification of vertebral 
deformities that do not correspond in all cases to vertebral 
fractures due to bone fragility. X-ray studies, depending on 
the type and severity of spinal height reduction, make it pos-
sible to identify three types of vertebral fractures: wedge-
shaped (anterior), biconcave (middle), and total vertebral 
collapse. To arrive at a more accurate identification, other 
methods of assessment exist, providing more or less quanti-
tative analyses of spine deformation. These methods may be 
divided into two classes: (a) semi-quantitative (SQ) visual 
methods and (b) quantitative morphometric methods. The 
SQ methods are based on an initial phase of visual evalu-
ation of images of the spine for a differential diagnosis of 
vertebral deformities providing; therefore, a visual gradation 
of osteoporotic vertebral fractures considered mild, moder-
ate, or severe (the Genant criteria) (Fig. 1).
Vertebral morphometry This is a quantitative method for 
the diagnosis of vertebral fractures based on the measure-
ment of vertebral height, and is carried out on the images 
of lateral projections of the thoraco-lumbar spine, per-
formed by the conventional radiology (MRX) or with DXA 
(MXA), using VFA software (vertebral fracture assessment) 
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that makes it possible, using radiation doses (50 µSv, about 
1/100 lower compared to conventional radiography) to cap-
ture the entire dorsal and lumbar spine in a single image 
while providing contextual measurements of vertebral body 
height limited to the T4–L4 area. The vertebral morphom-
etry technique is applied to images to assess the severity of 
vertebral fractures previously diagnosed by means of SQ, 
and to evaluate the possible occurrence of new fractures or 
a worsening of preexisting fractures during patient follow-
up. However, vertebral morphometry cannot be performed 
separately from a previous qualitative X-ray analysis to rule 
out deformity due to causes other than osteoporosis.
d. Spinal MRI
Fig. 1  Evaluation of spinal deformities based on Genant criteria
Table 2  Levels I and II laboratory tests
a Corrected serum-calcium (mg/dL): total serum-calcium levels (mg/dL) + 0.8 [4 − albumin in g/dL]
First-level tests Level II tests
 ESR  Ionised calcium
 Complete blood count  Thyroid stimulating hormone (TSH)
 Total protein + protein electrophoresis  Parathyroid hormone (PTH)
 Serum-calcium  levelsa  25-OH-vitamin D
 Phosphoraemia  Cortisol after overnight suppression test with 1 mg of dexametha-
sone
 Total alkaline phosphatase  Free Androgen Index (in males)
 Creatininaemia  Serum and urine immunofixation
24 h urinary calcium  Antitransglutaminase antibodies
 Specific tests for associated diseases (e.g., % ferritin and transferrin 
saturation, tryptase, etc.)
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The use of MRI in instrumental diagnoses of vertebral 
fragility fractures is indicated when several vertebrae are 
involved, because it makes it possible to determine- on the 
basis of the presence of signal changes in T2 and STIR, 
of bone oedema—to distinguish recent fractures from older 
ones, and to identify vertebrae, not yet deformed, presenting 
signs of impending structural failure.
e. Spinal CT
Using vertebral CT, it is possible to study the bone com-
ponent of the fractured vertebra in detail, and to obtain infor-
mation, for example, possible dislocation of bone fragments 
into the medullary canal in cases of traumatic fracture. CT 
is not indicated in routine evaluations of osteoporosis, but 
can be a useful investigation complementary to MRI in some 
cases [28–34].
Laboratory diagnosis
The first and second-level laboratory tests (Table 2) play a 
key role in the diagnosis of osteoporosis, inasmuch as they:
1. permit differential diagnoses, with other metabolic dis-
eases of the skeleton, that may result in a reduced BMD;
2. may make it possible to diagnose forms of secondary 
osteoporosis;
3. can help to guide pharmacological choices and provide 
useful elements for evaluating adherence to therapy
First-level tests are key elements in the diagnosis of 
osteoporosis. In fact, if they are normal, it is possible to 
exclude; in 90% of cases, other metabolic diseases of the 
skeleton or forms of secondary osteoporosis. Second-level 
tests are crucial when seeking to identify secondary forms of 
osteoporosis, and their choice must be based on the medical 
history and clinical evaluations of individual patients.
Bone turnover markers
Bone turnover markers are mainly used to obtain informa-
tion about the extent of new-bone-formation and resorp-
tion processes. They are overall indicators of skeletal 
remodelling, and, therefore, vary considerably at analytical 
and biological level: therefore, there is no indication for 
their use in routine evaluations of individual patients. In 
population studies, especially in postmenopausal women, 
they may prove useful when seeking to estimate the risk of 
fracture, irrespective of BMD. They have also been used 
widely in clinical trials aimed at monitoring the efficacy 
and mechanism of action of new drugs. Those commonly 
used in the assessment of bone neoformation are osteocal-
cin, bone isoenzyme of alkaline phosphatase (B-ALP), and 
type I collagen propeptides (PINP and PICP), while the 
most common markers of resorption are urinary pyridino-
line (PYR), urinary deoxypyridinoline (DPYR), and serum 
levels of type I collagen telopeptides (NTx, CTx). Their 
significant alteration makes it possible to orient diagno-
sis towards primary or secondary diseases typical of the 
skeleton (Paget’s disease of bone, osteomalacia, hypophos-
phatasia, bone metastases, etc.). Because it is possible to 
find significant changes in markers after a few weeks after 
beginning the treatment, it has been proposed that they be 
used also to evaluate patient adherence to drug treatment.
Genetic evaluation
Polymorphism of genes encoding collagen type 1 
(COLIA1), oestrogen (ER), and vitamin D (VDR) recep-
tors has been proposed as possible genetic determinants 
of the risk of osteoporosis. Each of these polymorphisms 
only accounts for less than 30% of the variance found in 
bone mass and even less than that when it comes to risk of 
fracture. Therefore, routine screening of genetic polymor-
phisms is not indicated either for fracture risk assessment 
or for determining therapeutic choices. Genetic analysis 
is, however, recommended in those rare cases where clini-
cal and laboratory tests suggest a monogenic bone disease 
(e.g., hypophosphatasia, Gaucher disease, and juvenile 
osteoporosis due to COL1A1 mutations) [23, 35, 36].
Non‑pharmacological measures 
for osteoporosis prevention and treatment
Osteoporosis prevention consists of using measures to 
prevent or slow down the onset of the disease. Treat-
ment is directed, instead, to subjects already suffering 
from osteoporosis, with or without preexisting fractures 
but with a high first-fracture or further fragility fracture 
risks. Prevention is first implemented and generally con-
sists in the correction of risk factors. Non-pharmacological 
Table 3  Calcium requirements at different ages and under different 
conditions
Calcium requirements mg/day
1–5 years 800
6–10 years 800–1200
11–24 years 1200–1500
25–50 years 1000
Pregnant or nursing 1200–1500
Postmenopausal women receiving oestrogen/men 
50–65 years of age
1000
Postmenopausal women without oestrogen treatment/
men aged > 65 years of age
1200
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intervention and elimination of modifiable risk factors 
(smoking, alcohol abuse, and environmental risks of falls) 
should be recommended for all.
Nutritional approach
Calcium
An adequate intake of calcium increases the density of the 
bone matrix in children and adolescents, maintains it in 
adults, and slows down its loss in women after menopause. 
The main source of calcium is milk and its derivatives, and, 
to a lesser extent, nuts (almonds), some vegetables (cab-
bage, spinach, and turnips) and pulses. The average calcium 
intake in the Italian population is insufficient, especially in 
the elderly. This dietary deficiency may contribute to nega-
tive calcium balance and to secondary hyperparathyroidism. 
Daily calcium requirements depend on age and certain con-
ditions (Table 3).
Supplemental calcium is especially indicated during preg-
nancy and lactation. Supplementation of calcium intake and 
calcium supplements in the diet, and this intervention alone, 
has been shown to produce modest increases in densitom-
etry in women with deficient dietary intakes and in women 
5 years after the onset of menopause. It has been reported 
that the sole administration of calcium does not produce a 
complete, but only a slight reduction in fracture risk, par-
ticularly in the elderly, but the most convincing documenta-
tion of its anti-fracture efficacy has been shown when it is 
administered in combination with vitamin D. The efficacy of 
an adequate calcium intake, as well as vitamin D, is propor-
tional to the severity and the frequency of the deficiencies 
in the population examined.
The risk of non-oxalic kidney stones can increase with 
the intake of calcium supplements, which is reduced with 
a diet rich in calcium, and the safety of calcium supple-
ments is questioned as regards possible increases in vas-
cular calcification and cardiovascular risk: although the 
most recent publications have not confirmed correlations 
between calcium intake and cardiovascular diseases, it is 
recommended that calcium supplementation adheres to the 
following guidelines:
1. Always estimate diet calcium intake by means of a brief 
questionnaire before prescription;
2. Always try to ensure an adequate intake of calcium from 
food and water rich in calcium;
3. Use dietary supplements only when calcium assumption 
is insufficient, indicating intake at meals and the mini-
mum dose necessary to satisfy requirements, possibly 
dividing intake into a number of doses (for example, 
500 mg at lunch and 500 mg at dinner) [37–44].
Vitamin D
Vitamin D is contained almost exclusively in animal fats, 
fish, liver, milk, and dairy products, while the amount of 
vitamin D in some vegetable fats is negligible; approxi-
mately 20% of circulating vitamin D derives from food, 
while it is largely produced by endogenous synthesis in the 
skin following exposure to UVB sun rays, a process increas-
ingly less efficient with advancing age. Consequently, there 
is a frequent need for supplementation, especially in old age, 
with vitamin D (cholecalciferol or ergocalciferol, namely 
D3 or D2), which, if associated with an adequate intake of 
calcium, has proved useful in the primary prevention of frac-
tures, in the elderly.
The effects of vitamin D supplementation on BMD are 
modest on average, proportional to the degree of deficiency 
and documented mainly only as regards the femur. The anti-
fracture effect of vitamin D is modest and documented, not 
for vertebral, but only for hip and non-vertebral fractures, 
and seems to be mediated also by a reported reduction in the 
risk of falling; in all cases, adequate calcium and vitamin 
D are a prerequisite for all specific drug treatment, because 
the lack of calcium or vitamin D is one of the most common 
causes of failure or reduced response to drug therapy for 
osteoporosis. A slight but significant reduction in mortality 
in the elderly associated with the use of cholecalciferol has 
also been reported, but there is currently no evidence of 
extra-skeletal benefits, although there is a strong pathophysi-
ological rationale for this. The current indications on how to 
interpret different levels of 25 (OH) D are shown in Table 4.
Risk conditions for hypovitaminosis D are well known, 
and there exists a wide therapeutic safety range regarding 
vitamin D supplementation, due to the regulation of physi-
ological mechanisms of vitamin D hydroxylation. Dosage of 
serum levels of 25 (OH) D is considered to be the best indi-
cator of vitamin D levels, even if, since it is not a low-cost 
procedure, it is not always justified from an economic point 
of view, especially in the elderly where hypovitaminosis D is 
known to be considerably widespread condition. It is, there-
fore, not recommended as a routine evaluation, let alone as a 
screening test, but must be reserved for cases of uncertainty 
featuring comorbidities or risk of severe hypercalcemia. If 
Table 4  Interpretation of plasma levels of 25 (OH) D
nmol/L ng/mL Interpretation
< 25 < 10 Severe deficiency
25–50 10–20 Deficiency
50–75 20–30 Insufficiency
75–125 30–50 Ideal range
125–375 50–150 Possible side effects
> 375 > 150 Intoxication
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the usually recommended doses (< 4000 IU/day) are used, 
it is not considered essential to perform 25 (OH) D dosage, 
even for the purpose of monitoring. When deemed appropri-
ate, a 25 (OH) D blood dosage can be performed to obtain 
a steady state (approximately 3–6 months after the start of 
supplementation) to check that the dose is adequate and 
to allow for possible dose adjustments. The objective is to 
reach a circulating concentration of 25 (OH) D of between 
30 and 50 ng/mL (75–125 nmol/L), that is stable over time.
Vitamin D supplementation
Vitamin D deficiency is so common in Italy in the elderly 
population in general and in subjects at risk of fragility 
fracture, that it may be considered the rule, even without 
measuring plasma 25 (OH) D. When, as often happens, it is 
not possible to correct this deficiency through diet or with 
an appropriate and non-risky exposure to sunlight, it is nec-
essary to use cholecalciferol supplements, preferably in a 
daily or weekly dose, avoiding the hydroxylated metabo-
lites in position 1 (calcitriol and alfacalcidol) that overcome 
endogenous regulation, but may expose the patient to risk 
of hypercalcemia. Daily vitamin D supplementation is a 
more physiological approach to supplementation; however, 
to improve adherence to treatment, equivalent weekly or 
monthly dosage doses are justified from a pharmacological 
point of view.
If the administration of high doses (boluses) is deemed 
appropriate, it is recommended that these do not exceed 
100,000 IU, because, at higher doses, an increase of bone 
resorption indices has been seen, and also a paradoxical 
increase in fractures and falls.
To rapidly obtain adequate serum levels of 25 (OH) D,  D3 
is preferred to  D2, and it is better to administer this orally, 
limiting the use of intramuscular application to patients with 
severe malabsorption syndromes.
The aim of vitamin D deficiency and insufficiency ther-
apy is to restore normal serum levels and thus of depos-
its of 25 (OH) D, in a brief time. The cumulative dose to 
be administered within a few weeks may vary depending 
on the severity of the deficiency and the body mass. The 
weekly administration of 50,000 IU of cholecalciferol dur-
ing 2–3 months can restore values to normal levels in severe 
deficiency cases. This must be followed by a maintenance 
dose of up to 2,000 IU daily or equivalent doses adminis-
tered weekly or monthly. These doses should be reduced 
accordingly if basal values are achieved, for example, or in 
the case of failure.
As to the use of alternative hydroxylated metabolites of 
vitamin D (calcifediol, 1-alpha-calcidiol, and calcitriol), 
there are still no adequate comparative dose-equivalent 
evaluations with respect to vitamin D, or documentation 
of anti-fracture efficacy analogous to those available for 
cholecalciferol’s ability to provide rationale-based indica-
tions under specific conditions. In particular: (a) calcife-
diol [25 (OH)D3], which induces a more rapid increase 
in levels of 25 (OH) D, due to different pharmacokinetics 
and a lower volume of distribution relative to cholecal-
ciferol, may be indicated in the case of 25-hydroxylation 
deficits (e.g., severe liver failure, male hypogonadism, 
and inactivating mutations of the gene encoding enzyme 
25-hydroxylase), obesity, and intestinal malabsorption; 
(b) calcitriol [1-25 (OH)2D3] is indicated in conditions of 
1-alpha-hydroxylase deficiency (i.e., moderate-to-severe 
renal insufficiency, hypoparathyroidism, and mutations of 
the gene encoding enzyme 1-alpha-hydroxylase) and intes-
tinal malabsorption.
The 1-hydroxylated metabolites of vitamin D can induce 
hypercalcaemia and hypercalciuria, which, therefore, must 
be checked by means of periodic monitoring of serum and 
urinary calcium. Even in these cases, cholecalciferol intake 
should be ensured in view of its known autocrine and par-
acrine activities and its potential extra-skeletal effects. If 
calcitriol and 1-α calcidiol are used, a useful contribu-
tion of cholecalciferol is ensured with a view to achieving 
the recommended circulating concentrations 25 (OH) D3 
[45–54].
Other nutrients
Increases in protein consumption in patients with inadequate 
intake reduce the risk of hip fracture in both genders. Ade-
quate protein intake is necessary to maintain the functions 
of the musculoskeletal system, but also to reduce the risk of 
complications after an osteoporotic fracture. In fact, an ade-
quate protein intake (1.0–1.2 g/kg/day with at least 20–25 g 
of proteins per meal) associated with physical resistance 
exercises (muscle-strengthening exercises) increases muscle 
mass and strength. Even other micro-nutrients such as zinc, 
silicon, vitamin K, vitamin E, vitamin B6, vitamin B12, and 
magnesium seem to have a protective role with regards to 
bone and muscle.
Physical activity
It is a well-known fact that even short periods of immobilisa-
tion adversely affect bone mass, and it is, therefore, impor-
tant to maintain an appropriate level of physical activity, 
keeping in mind, however, that competitive physical activ-
ity in young women may lead to exaggerated hormonal and 
nutritional abnormalities that can be detrimental to bone.
Types of physical activity divided into two basic 
categories:
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1. low or high impact aerobic activity (e.g., jogging, soc-
cer, basketball, volleyball, baseball, racket sports, and 
gymnastics).
2. muscle-strengthening activities (weight lifting, body 
building, swimming, cycling or exercise bikes, and use 
of weights for static exercises).
One of the most common forms of aerobic exercise 
is walking, which is very well accepted by older people, 
because it is bland, can be self-managed, and easily prac-
tised. Meta-analyses, however, have highlighted the absence 
of significant effects of walking on lumbar and femoral 
BMD. In postmenopausal women, aerobic training, and, in 
particular, high-intensity and speed walking, interspersed 
with jogging, climbing stairs, and stepping, can limit reduc-
tions in bone density. Multi-component training, including 
moderate-to-high impact exercises, muscle strengthening, 
and balance exercises, has a positive effect on both the femur 
and the lumbar spine. Training with vibrating platforms is of 
dubious efficacy in improving bone density at specific sites 
such as the femoral neck and spine. Some epidemiological 
studies have shown a correlation between physical activity 
and lower risk of fracture.
Prescription of exercise in the elderly and osteoporotic 
patient should always be preceded by a thorough medi-
cal examination, which is useful to define the intensity of 
feasible exercise based on muscle strength, balance, gait, 
cardiovascular function, and comorbidities. Encouragement 
of even modest physical activity in the elderly can help to 
reduce the risk of fall and therefore of fracture. The recom-
mendation to carry out a minimum of physical activity (walk 
more than 30 min a day, outdoor, if possible), despite the 
inadequacy of documentation attesting its benefit to bone 
mass, appears acceptable due to its effects on the risk of 
falling and, indirectly, on 25 (OH)D levels [55–64]
Prevention of falls
Most fractures, especially of the hip, are caused by falls, 
and the risk factors for these (physical disabilities, balance 
disorders, neuromuscular disorders, visual impairment, 
cardiovascular disease, past medical history of falls, drug 
treatment, and cognitive deficits) are often modifiable in a 
context of multidisciplinary intervention.
Physical activity, in particular personalized muscle-
strengthening exercises, balance, and gait rehabilitation, are 
able to reduce the risk of falls related to trauma in the elderly. 
Individual evaluation of fall risks and associated prevention 
recommendations such as a reduction in the use of psycho-
tropic drugs has a positive impact on falls. A fall-prevention 
strategy for the elderly, including adequate intake of vitamin 
D, physical exercise, and education regarding risks within the 
home, is highly recommendable.
An alternative or, rather, supplementary strategy capable of 
reducing the risk of hip fracture is that of mitigating loading on 
that skeletal segment using “hip protectors.” The use of these 
orthosis has yielded mixed benefits so, for the moment, their 
use is recommended only in institutionalised patients with a 
very high risk of falling.
Assessment of the home environment is important. Many 
obstacles or hazard, like poor lighting, wires or carpets, inad-
equate footwear, and the presence of pets, are modifiable.
Integrated approaches for secondary prevention 
of fractures
The secondary prevention of fragility fractures, aimed at 
preventing re-fracture, is very complex and all the strategies 
adopted over the years have yielded disappointing results. 
In fact, OSMED data, recently published in Italy by AIFA, 
indicate that approximately 80% of patients with fragility 
fractures (femoral or vertebral), or chronic treatment with 
glucocorticoids, do not receive either a correct diagnosis or 
adequate medical treatment, and that after 1 year, only about 
50% of patients continue to follow their therapy correctly. It 
is, therefore, necessary to develop new integrated and mul-
tidisciplinary models, such as Orthopaedic and Geriatric 
Co-Management, Fracture Unit and Fracture Liaison Ser-
vices. These are flexible models based on improved com-
munication between the various specialists and the general 
practitioners involved in the management of patients with 
fragility fractures. The strength of these multidisciplinary 
models is their ability to be implemented in the context of 
very different clinical and organisational systems. The role 
of nurses with specific expertise in the field of osteoporo-
sis and fragility fractures (Nurse Case Manager or Bone 
Care Nurses) is essential for them to function properly. It 
is the nurses who must not only ensure the care of patients 
with fragility fracture during hospitalisation by fostering 
proper communications between the orthopaedic team, the 
various specialists involved and the general practitioner, 
but from admission on devise an educational programme 
for patients and their caregivers to ensure proper use of 
drugs, to improve adherence to treatment and prevent falls 
[65–70].
Drug intervention
Pharmacological thresholds
The treatment of osteoporosis should aim at reducing 
the risk of fracture in high-risk subjects and the values 
of the DXA T-score, availed of by the WHO to establish 
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diagnostic thresholds, cannot be used to identify pharma-
cological intervention thresholds. In fact, the risk of frac-
ture should always be obtained by integrating densitomet-
ric data with other important clinical factors such as age, 
steroid therapy, smoking, thinness, etc., combined to deter-
mine fracture risk, regardless of BMD. This can be quickly 
obtained using mathematical algorithms that quantify the 
risk in terms of “10-year fracture risk” such as  FRAX® or 
DeFRA and which are particularly important if the patient 
is not fractured.
The history of previous osteoporotic fractures, adjuvant 
hormonal block in men with prostate cancer and in women 
with breast cancer, and chronic glucocorticoid therapy, 
in particular prednisone doses equivalent to ≥ 5 mg/day, 
are associated with such a high risk of fracture that the 
decision to initiate drug therapy may rule out the need to 
acquire densitometric values.
Anti‑osteoporotic drugs
The drugs available in Italy for the treatment of osteopo-
rosis can be divided into two categories: anti-resorptive 
(or anti-catabolic) and anabolic. All the drugs belonging 
to these two categories are able to significantly reduce the 
risk of vertebral fractures, while their ability to reduce 
risks of non-vertebral and femoral fractures has been dem-
onstrated in only a few cases; their reimbursement by the 
National Health Service (NHS) is governed by Note 79, 
and for some of these drugs (denosumab, strontium rane-
late, and teriparatide), it is necessary that an authorized 
specialist Treatment Plan be endorsed. In any case, it is 
necessary for the physician to aim at ensuring adequate 
therapeutic adherence by means of appropriate informa-
tion to patients and the careful choice of the medication 
prescribed.
Anti‑catabolic drugs
Bisphosphonates Bisphosphonates (BP) are synthetic ana-
logues of pyrophosphate compounds able to fixate selec-
tively on bony surfaces subject to remodelling. They block 
osteoclast activity at these locations, reduce bone turnover, 
and increase bone density with a different mechanism of 
action as a function of the presence or absence of an amino 
group. BP is absorbed by the 0.5–5% of the gastrointestinal 
tract, and is contraindicated in patients with hypocalcaemia, 
gastrointestinal diseases, renal failure (CCr < 30  mL/min), 
or if pregnant or nursing.
Etidronate and clodronate are BP lacking amino groups 
that increase vertebral density and maintain femoral neck 
density in postmenopausal women.
Etidronate is not indicated in osteoporotic patients, and 
clodronate was is effective in reducing clinical fractures at 
a dose of 800 mg/day orally. The anti-fracture efficacy of 
intramuscular clodronate therapy at the most commonly used 
dosage in Italy (100 mg/week or 200 mg every 2 weeks) has 
not been definitively demonstrated, and therefore, it must 
be regarded as a second-choice drug for the treatment of 
osteoporosis.
The efficacy of alendronate and risedronate for the pre-
vention of vertebral and non-vertebral fractures (including 
hip) is extensively documented. Their anti-fracture efficacy 
has been demonstrated with the daily administration of the 
two drugs, and it can be used in weekly administrations 
(70 mg/week of alendronate and 35 mg/week or 75 mg 
2 days/month for risedronate) on the basis of the equivalence 
of different formulations in determining increases in BMD. 
Recently, in Italy, formulations of alendronate in a liquid 
form have become available.
Ibandronate is registered based on studies using a dosage 
of 2.5 mg/day. At this dose, it has proven only effective in 
reducing the risk of vertebral fractures, and has been sub-
sequently marketed at a dosage of 150 mg/month or 3 mg 
iv/3 months, or cumulative-bioavailable double doses to 
those used in the pivotal studies.
Zoledronic acid (5 mg/iv/year) is registered for the treat-
ment of osteoporosis based on a study that documents 
clearly reduced risk of vertebral, non-vertebral, and hip 
fractures after 3 years of treatment. In one ancillary study, 
also a reduction in overall mortality is demonstrated.
Alendronate, risedronate, and zoledronate also have been 
registered for the treatment of male and corticosteroid-
induced osteoporosis.
Neridronate is the only BP indicated for the treatment 
of osteogenesis imperfecta, and in Italy, it is currently indi-
cated for the treatment of algodystrophy (complex regional 
pain syndrome type I) on the basis of data obtained in a 
randomised controlled trial.
As for adverse events due to BP, these can be classified 
as follows:
(a) Acute Phase Reaction: The administration of amino-
BP by the iv route (but also of oral BP in high doses) 
may be associated with an influenza-like syndrome 
with a duration of 1–3 days, and characterized by fever 
and widespread musculoskeletal pain, more frequent, 
and severe after the first administration of the drug. Its 
symptoms are well controlled with oral acetaminophen, 
and only rarely, is it necessary to administer corticos-
teroids.
(b) Atypical femoral fractures (AFF): these are transverse 
stress fractures whose diagnosis requires compliance 
with precise classification criteria. The incidence of 
these fractures is very low (3.2–50 cases per 100,000 
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person/year), but is positively correlated with the dura-
tion of treatment with BP. Based on the available data, 
and given the rarity of these events, the risk/benefit 
ratio in the use of BP for the prevention of fragility 
fractures is clearly in favour of the benefit. To minimize 
the risk of AFF in patients treated with BP, it may be 
useful to: (a) consider periods of “therapeutic vaca-
tion,” after careful assessment of the benefit–risk ratio; 
(b) monitor and correct other risk factors for atypical 
fractures (chronic use of glucocorticoids, hypovita-
minosis D, chronic use of proton pump inhibitors, and 
presence of skeletal diseases other than osteoporosis).
(c) ONJ (OsteoNecrosis of the Jaw) or osteomyelitis of 
the jaw. This event is very rare in patients who use BP 
for the treatment of osteoporosis (1:10,000 patients 
treated), but it increases if they are subjected to oral 
cavity interventions with bone tissue exposure. In 
patients starting treatment with BP for osteoporosis, 
there is no need for prior dental examination and treat-
ment. In cases of invasive dental surgery (extraction), 
we recommend the use of topical antiseptics (chlo-
rhexidine mouthwash 0.20%) and antibiotics (amoxi-
cillin, optionally in combination with metronidazole) 
2 days prior to surgery, and for 6–8 days after, espe-
cially if there are individual risk factors (diabetes, 
immunosuppression, use of steroids, smoking, and 
alcohol), while a brief suspension of the BP is car-
ried out.
Duration of  bisphosphonate therapy In view of the 
adverse events associated with long-term therapy with 
BP, the need for continued treatment should be reviewed 
at regular intervals. Based on available data, risk reas-
sessment should be carried out after 5 years of treatment 
with alendronate, ibandronate, and risedronate and after 
3 years for treatment with zoledronate. Suspending treat-
ment for 12–24 months in patients who have received oral 
BP for over 5 years and are at low risk of fracture is advis-
able. However, continuation of treatment up to 10 years 
(maximum duration of treatment hitherto investigated) in 
patients at high risk of fracture, such as those with femo-
ral T-score < − 2.5 or with prior vertebral fractures and 
T-score femur less than − 2.0 is recommended. In high-
risk patients treated with zoledronate, continued treatment 
with zoledronate for other 3 years is indicated.
Denosumab Denosumab is a human monoclonal antibody 
capable of neutralising RANKL, a cytokine that interacts 
with the RANK receptor on the membrane of preosteoclasts 
and mature osteoclasts, affecting their recruitment, matu-
ration, and survival. Pivotal studies were conducted using 
60  mg of subcutaneous denosumab every 6  months. This 
dose ensures almost total suppression of bone turnover, and 
determines an increase in BMD higher than that obtainable 
with BP both in trabecular and cortical bone with a con-
sequent reduction of fragility fractures at all skeletal sites. 
Denosumab is effective in reducing the risk of fractures in 
women with breast cancer treated with aromatase inhibitors, 
as well as in men with prostate cancer being treated with 
anti-androgens. In very severe cases of established osteopo-
rosis, the combination denosumab/teriparatide therapy has 
resulted in a marked increase in BMD. Similar advantages 
in terms of increase in BMD are obtained with sequential 
teriparatide–denosumab therapy. Unlike BP, discontinua-
tion of treatment with denosumab is followed by an abrupt 
increase of bone turnover, and by a rapid loss of BMD. 
Therefore, the suspension of denosumab generally requires 
the patient to begin, as soon as possible, the treatment with 
BP at an adequate dosage.
Treatment with denosumab may, sometimes, cause 
hypocalcaemia; therefore, this must be corrected and pre-
vented by adequate intake of calcium and vitamin D. In the 
postregistration extension studies, rare cases of ONJ and 
AFF were seen.
Hormone replacement therapy (HRT) Menopausal women 
undergoing oestrogen treatment, on its own or in combina-
tion with progestin, and with tibolone, are able to reduce 
bone turnover and increase bone mass. Oestrogen anti-
fracture efficacy has been confirmed by several randomised 
trials and major observational studies (especially the WHI 
study). Despite the positive effect on fractures, to which may 
be added a reduction in the risk of colorectal cancer, these 
drugs entail an increased risk of breast cancer, stroke and 
thromboembolic events. Therefore, HRT is no longer indi-
cated for the treatment or prevention of osteoporosis. For 
women suffering from the climacteric syndrome, especially 
if still within the 50–55 age-range, temporary administra-
tion of oestrogen or oestrogen plus progestin (depending on 
whether or not there is an intact uterus) may be considered 
in some way to be physiological and be proposed, it is also 
effective for the prevention of osteoporosis.
Selective oestrogen receptor modulators (SERMs) SERMs 
are synthetic compounds capable of binding with oestro-
gen receptors that produce agonist effects at bone and liver 
level, and antagonist effects at breast and genitourinary tract 
level. The SERMs currently approved in Italy for the pre-
vention and treatment of osteoporosis are raloxifene and 
bazedoxifene. The pivotal trial MORE raloxifene (60 mg/
day) reduced the incidence of new vertebral fractures, (but 
not those of non-vertebral and femoral fractures) and inva-
sive breast cancer, accentuating vasomotor phenomena in 
some patients.
Bazedoxifene (20  mg/day) significantly reduces the 
risk of vertebral and non-vertebral fractures (but not 
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hip fractures) in high risk of fracture women treated for 
3–5 years. Compared to raloxifene, bazedoxifene has a 
higher anti-oestrogenic effect in the uterus in the absence 
of significant side effects. SERMs, like HRT, are associated 
with increased risk of thromboembolic events, and are not 
recommended in patients who have had, or who are at risk 
of venous thrombosis [23, 71–91].
Anabolic drugs
Teriparatide The administration of parathyroid hormone, 
and in particular, of its active fragment 1–34 (teriparatide), 
stimulates both bone formation and resorption, with a pre-
dominant effect on neoformation (anabolic window) that is 
evident especially during the first 12 months of treatment. 
Increases observed in BMD values are significantly higher 
than those obtained with BP in trabecular bone only, with 
an increase of close to 10%, in spinal BMD at 18 months. 
However, treatment with teriparatide also determines an 
improvement in some geometrical characteristics of cortical 
bone related to resistance to fracture.
Teriparatide (20 µg/day sc) has proved capable of reduc-
ing vertebral and non-vertebral fractures in postmenopausal 
women, and currently, its administration cannot exceed a 
total of 24 months. On withdrawal of treatment, there is a 
rapid decline in densitometric values; therefore, it is advis-
able to start anti-resorptive therapy as soon as possible. Due 
to its high cost, it is reimbursed by the NHS for second-
ary prevention in patients with osteoporosis at high risk 
of fracture or “non-responsive” to anti-resorptive medica-
tions. Treatment with teriparatide is frequently associated 
with less severe disorders (nausea and cramps in the lower 
limbs) and increased incidence of hypercalcemia, usually 
asymptomatic. Teriparatide is contraindicated in patients 
with hyperparathyroidism, Paget’s disease of bone, severe 
renal failure, primary tumours, or skeletal metastasis or pre-
vious radiation therapy on the skeleton.
Dual‑action drugs
Strontium ranelate Treatment with strontium ranelate is 
effective when seeking to reduce risks of vertebral, non-
vertebral, and hip fractures in postmenopausal women with 
osteoporosis. This drug increases bone formation markers, 
and modestly decreases those for resorption. Increases in 
densitometry registered during therapy are approximately 
50% related to the higher molecular weight of strontium as 
compared to calcium. Since treatment with strontium rane-
late has also been associated with an increased risk of myo-
cardial infarction and thromboembolic events, it is contrain-
dicated in patients with ischaemic heart disease, peripheral 
arterial disease, or cerebrovascular disease, or a history of, 
or uncontrolled high blood pressure. Rare cases have been 
reported of serious allergic skin reactions, sometimes asso-
ciated with potentially fatal systemic symptoms such as 
DRESS (Drug Rash with Eosinophilia and Systemic Symp-
toms) and toxic epidermal necrolysis. The use of strontium 
ranelate is currently restricted to the treatment of severe 
osteoporosis in postmenopausal women or adult men at high 
risk of fractures, for whom treatment with other medicines 
approved for osteoporosis therapy is not feasible [92–94]
Kyphoplasty and vertebroplasty
Vertebral fractures often occur with sudden and rapidly pro-
gressing pain, not in relation to effective trauma, initially 
continuous, also felt at rest, and then when load-bearing.
The treatment of vertebral fractures in the acute stage 
involves conservative measures such as rest, use of corsets, 
and minor and major painkillers. Pain due to a vertebral frac-
ture usually begins to fade after 1–3 weeks, and disappears 
completely after a few months. In some cases, however, the 
pain can last for months in relation to the severity and loca-
tion of the fractured vertebra, which influences the develop-
ment or persistence of biomechanical instability.
Transpedicular injections of a synthetic material similar 
to cement within the fractured vertebral body may be accom-
panied by immediate cessation of pain.
The methods currently proposed to stabilize or 
reduce–stabilize vertebral fractures are vertebroplasty, in 
which cement under high pressure is injected with greater 
risk of leakage and pulmonary embolism, and kyphoplasty, 
in which the cement is introduced at low pressure with lower 
risk of leakage after the introduction of a balloon which 
is then inflated within the vertebral body often enabling a 
partial reduction of the deformity.
Vertebroplasty or kyphoplasty can only be recommended 
for patients with intractable pain for weeks, with due consid-
eration of the potential risks associated with the procedures 
and the uncertain benefits in the long term. The use of these 
procedures is, therefore, not indicated in patients with few 
or no symptoms.
However, it is essential that all patients with vertebral 
fragility fractures treated with vertebroplasty or kyphoplasty 
are prescribed a suitable pharmacological treatment, so that 
the presence of cement within the vertebral body, when there 
are systemic conditions for bone fragility, does not expose 
adjacent vertebrae to an increased risk of fracture [23, 95, 
96].
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